Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA

相似书籍

• Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020
  由: Jing Luo, et al.
  出版: (2023-02-01)
• Food and Drug Administration (FDA) Approvals of Biological Drugs in 2023
  由: Alexander C. Martins, et al.
  出版: (2024-09-01)
• Development on Cancer Therapeutic Drugs Approved by FDA in 2023
  由: Qing HUANG, et al.
  出版: (2024-07-01)
• FDA’s approval of resmetirom (Rezdiffra): a breakthrough in MASH management
  由: Muhammad Mazhar Azam, et al.
  出版: (2024-12-01)
• Pharmacists’ Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation
  由: Megan C. Herink, et al.
  出版: (2022-09-01)